Evolent Health, Inc.

Evolent Health, Inc. (EVH) Market Cap

Evolent Health, Inc. has a market capitalization of $329.3M.

Financials based on reported quarter end 2025-12-31

Price: $2.95

-0.15 (-4.84%)

Market Cap: 329.33M

NYSE · time unavailable

CEO: Seth Barrie Blackley

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2015-06-05

Website: https://www.evolenthealth.com

Evolent Health, Inc. (EVH) - Company Information

Market Cap: 329.33M · Sector: Healthcare

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.

Analyst Sentiment

76%
Strong Buy

Based on 29 ratings

Analyst 1Y Forecast: $6.38

Average target (based on 3 sources)

Consensus Price Target

Low

$4

Median

$6

High

$10

Average

$6

Potential Upside: 116.3%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 EVOLENT HEALTH INC CLASS A (EVH) — Investment Overview

🧩 Business Model Overview

Evolent Health Inc Class A (EVH) is a healthcare technology and services company with a primary focus on enabling value-based care delivery. The company provides a platform and suite of services to payers and providers aiming to improve clinical and financial outcomes. Evolent operates at the intersection of healthcare management, claims administration, technology enablement, and data analytics, helping healthcare organizations migrate from fee-for-service to risk-based and outcomes-driven reimbursement models. By partnering with provider groups and health plans, Evolent delivers both enterprise software solutions and care management services designed to optimize population health and enhance cost efficiencies.

💰 Revenue Streams & Monetisation Model

Evolent generates revenue through a mix of technology-enabled services, platform fees, and performance-based arrangements. Key revenue streams include: - **Platform & Administrative Fees:** Healthcare organizations pay recurring fees for access to Evolent’s proprietary platform and administrative services, which provide analytics, workflow tools, claims processing, and compliance solutions. - **Care Management Services:** Evolent delivers population health management, specialty care solutions (with a particular emphasis on oncology and cardiology), and clinical program management. These are typically monetized via per-member-per-month (PMPM) fees or similar engagement models. - **Shared Savings & Performance Incentives:** A portion of Evolent’s revenues can be tied to performance metrics, such as reductions in medical cost ratios or improvements in quality. Under certain arrangements, Evolent profits by sharing in the cost savings or quality bonuses generated for its healthcare partners. - **Consulting & Advisory Services:** Evolent also provides advisory services for organizations transitioning to value-based care, although these are a smaller contributor relative to recurring services. Revenue predictability is enhanced by multi-year contracts and the often sticky nature of core administrative and risk-partnership services.

🧠 Competitive Advantages & Market Positioning

Evolent Health is positioned as a leading enabler of value-based healthcare in the United States. Its competitive strengths derive from several areas: - **Integrated Platform:** Evolent offers a comprehensive solution that merges population health analytics, claims adjudication, care management, and specialty care — reducing IT fragmentation for clients and streamlining value-based operations. - **Specialty Care Expertise:** With sector-leading assets in complex specialties, notably oncology and cardiology, Evolent differentiates by targeting high-cost, high-variation areas of spend and delivering demonstrable results. - **Track Record & Partnerships:** The company has established a strong track record in reducing cost of care and improving quality metrics for prominent provider groups and health plans nationwide, supporting both organic client expansion and new logo wins. - **Regulatory Alignment:** Evolent’s solutions are closely aligned with ongoing policy trends (such as the shift toward Medicare Advantage and risk-bearing arrangements), which positions the company to benefit from structural industry changes. - **Data & Technology:** Proprietary analytics, actionable data insights, and scalable cloud infrastructure allow Evolent to continuously refine and adapt its offerings, ensuring relevance in a fast-evolving market.

🚀 Multi-Year Growth Drivers

Several structural trends offer sustained growth opportunities for Evolent Health: - **Shift from Fee-for-Service to Value-Based Care:** As reimbursement models across commercial, Medicaid, and Medicare lines of business increasingly favor provider risk assumption, demand for end-to-end enablement and risk management rises. - **Expansion of Risk-Based Contracts:** Both payers and provider systems are deepening engagement in full- and partial-risk arrangements, leading to broader adoption of Evolent’s PMPM and shared savings models. - **Specialty Care Management Penetration:** Growing expenditure in complex care areas (especially oncology and cardiology) drives demand for more sophisticated, evidence-based management solutions, where Evolent has established early leadership. - **Broader Geographic and Customer Expansion:** Evolent can expand its national footprint both through organic client wins and targeted acquisitions, leveraging network effects and cross-selling multiple service lines. - **Policy Tailwinds:** Policy initiatives (such as the proliferation of Accountable Care Organizations and Medicare Advantage) and regulatory incentives around interoperability and quality create long-term demand for platforms that can manage clinical risk and optimize care delivery.

⚠ Risk Factors to Monitor

Investors should remain aware of several key risks associated with Evolent’s business: - **Client Concentration:** A limited number of large customers can comprise a significant share of revenue, exposing the firm to contract renewal and pricing risks. - **Execution on Performance-Based Contracts:** A portion of Evolent’s earnings depend on the ability to achieve guaranteed cost savings or clinical quality targets; underperformance can affect revenues and margins. - **Regulatory & Policy Shifts:** Changes in healthcare reimbursement rules, regulatory frameworks, or government programs can alter growth prospects or impose new compliance burdens. - **Technology & Cybersecurity Exposure:** As a healthcare technology provider, Evolent must maintain robust, secure IT infrastructure and comply with evolving data privacy regulations (e.g., HIPAA). - **Competitive Pressure:** The healthcare technology and services sector is highly competitive, with both incumbent payers and new entrants developing capabilities across population health, care management, and claims administration. - **Integration Risks:** Expansion via M&A introduces complexity in integrating systems, personnel, and client relationships.

📊 Valuation & Market View

Evolent Health is typically valued on a mix of forward revenue, EBITDA, and, to a lesser extent, adjusted earnings multiples that reflect its recurring revenue base and growth orientation. The company’s valuation benchmarks versus both software-enabled healthcare services vendors and health IT pure-plays, often commanding a premium for its specialization in value-based care enablement, depth in specialty care management, and long-term customer contracts. Market consensus reflects optimism regarding the company’s ability to scale profitably as health systems move deeper into value-based models, although valuation can remain sensitive to margin variability and contract performance attestations. The capital-light, SaaS-enabled qualities enhance profitability potential as the revenue base expands and customer churn remains low.

🔍 Investment Takeaway

Evolent Health offers investors a pure-play exposure to the structural transformation of the U.S. healthcare system toward value-based and outcomes-driven care. The company’s integrated platform, specialty care expertise, and strong business relationships position it as a critical partner for payers and providers navigating the complex shift to risk-based reimbursement models. Compelling multi-year growth catalysts include secular policy trends, increasing risk-sharing adoption, and rising demand for specialty care management. However, investors should closely monitor execution on key contracts, the risk profile of performance-based incentives, regulatory developments, and the competitive landscape. For those seeking high-growth healthcare technology opportunities aligned with fundamental transformation of industry cost and quality dynamics, Evolent Health stands out as a differentiated leader.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Evoke Pharma, Inc. (EVH) reported revenues of $468.7M for the fiscal year ending December 31, 2025, but faced a significant net loss of $429.1M, translating to an EPS of -$3.76. The operating cash flow and free cash flow were both reported as zero, indicating a challenging financial position without positive cash generation. With total assets of $1.9B against total liabilities of $1.5B, the company has a net debt of about $837.8M. The stock price has suffered a dramatic decline of approximately 76.76% over the past year, raising substantial concerns regarding shareholder returns. Despite seeing growth in revenue, the negative cash flow and escalating losses weigh heavily on its overall financial health and valuation. The average price target from analysts sits at $6.38, offering a potential upside from its current trading price of $2.25. However, this potential is countered by the recent uninspiring performance in the market, suggesting caution for investors."

Revenue Growth

Fair

Revenue is substantial at $468.7M, but recent trajectory is unclear.

Profitability

Neutral

Company is posting significant losses with a net income of -$429.1M.

Cash Flow Quality

Neutral

Operating and free cash flow are both zero; cash generation is a concern.

Leverage & Balance Sheet

Caution

High net debt of $837.8M with considerable assets but also significant liabilities.

Shareholder Returns

Neutral

Severe decline in stock price (-76.76%), indicating poor returns to shareholders.

Analyst Sentiment & Valuation

Caution

Analysts set a price target indicating potential upside, but risk factors are high.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is confident about long-term margin expansion—highlighting strong Q4 execution, ~30% 2026 revenue growth, and a “very significant tailwind” if Performance Suite reaches its 7%–10% margin target (potentially $160M–$220M total margin at year-end run-rate). However, the Q&A exposed how much of 2026 profitability is being pressured by conservative reserving during the ramp of large new contracts (not just membership mix). For instance, analysts questioned why MER is reserved around 103% for a CVS-like contract despite enhanced terms and fee/acuity adjustments; management’s answer pointed to initial data-flow/implementation uncertainty and IBNR mechanics, including an explicit ~$13M margin add in the EBITDA bridge—resulting in a $25M midpoint EBITDA headwind from new-launch timing/reserving. Overlaying this is the $40M Specialty T&S headwind from One Big Beautiful Bill and assumed ~40% exchange membership reduction. The upside narrative is real, but near-term execution risk is the story in the numbers.

AI IconGrowth Catalysts

  • 2026 Performance Suite launches expected to generate ~$900M of 2026 revenue (go-live dates Q1/Q2); increased from prior estimate of $550M due to membership shifts and scope expansion on one new contract
  • Highmark oncology expanded partnership (expected go-live May 1): >$550M 2026 revenue and >$800M 2027 revenue; structured under enhanced Performance Suite
  • Oncology Performance Suite rollout in an additional state with an existing national partner (additional growth contribution within Performance Suite oncology)
  • Customer retention/expansion momentum: retained specialty T&S logos covering >98% of 2025 revenue; ~90% of Performance Suite revenue under the enhanced model with all key customers retained and 2 major new enhanced-model customers signed in 2025

Business Development

  • Highmark (major oncology partnership announced in November; expanded since then across additional geographies/capabilities; go-live May 1; ~1.35B+ revenue across 2026-2027)
  • Existing national partner (Performance Suite launched in oncology in an additional state; partner not named)
  • Enhanced Performance Suite renegotiations: contracts moved to enhanced Performance Suite model (no named customer beyond Highmark; also referenced 'Aetna' contract structure as a reference point)

AI IconFinancial Highlights

  • Q4 2025 revenue: $469M; adjusted EBITDA: $37.8M (exceeded midpoint of guidance)
  • FY2025 baseline (ex-ACO divestiture) revenue: $1.77B; adjusted EBITDA would have been ~$141M
  • 2025 MER: 89% excluding ECP; Q4 MER: 95% excluding ECP driven by out-of-period true-ups (recognized full-year savings shared with clients); underlying medical trend stable
  • 2026 revenue guidance: $2.4B to $2.6B; midpoint implies ~30% growth; includes ~$100M lost revenue from existing Performance Suite clients due to exchange-related membership contraction and some market exits; mitigated by new Performance Suite launches
  • 2026 adjusted EBITDA guidance: $110M to $140M; midpoint impacted by (1) new contract timing/reserving headwind and (2) One Big Beautiful Bill impact
  • One Big Beautiful Bill: eliminated ~ $40M of contribution from expected exchange membership disenrollment/customer plan closures
  • Specialty T&S exchange impact: onetime ~$40M headwind to 2026 Specialty T&S revenue consistent with high-end ~40% decline in exchange membership (net of acuity shifts); excluding exchange, T&S expected +$5M incremental revenue and margin at midpoint
  • Performance Suite MER for 2026: expected ~93% at midpoint of guidance (up from 89% in 2025 excluding ECP); MER progression expected to peak in Q3 due to Highmark onboarding and strengthening claims reserves; underlying medical claims expected roughly consistent throughout the year
  • Analyst/management numeric clarification in Q&A: new contracts reserving methodology drives initial conservative reserves and an explicit added margin of ~ $13M on EBITDA bridge; despite enhanced contract retroactive fee adjustments, MER still reserved at ~103% (question referenced CVS contract) due to ramp-up, IBNR/IBNR coverage, and implementation data-flow timing

AI IconCapital Funding

  • End of 2025 net debt: $782M (below expected $805M to $840M range); no maturities until late 2029
  • Q&A/operating note: client overpayment mentioned by management—$15M overpayment included in results; when repaid it will negatively impact 2026 cash flow
  • 2026 cash flow from operations: at least $10M to $20M after paying ~$60M cash interest expense
  • 2026 cash/CapEx: invest $25M to $30M in software development and CapEx
  • Shareholder return drivers: management highlighted potential tailwind if Performance Suite reaches 7% to 10% target margin; no explicit buyback authorization disclosed in transcript

AI IconStrategy & Ops

  • Efficiency/automation program targeting authorization automation: long-term goal to automatically approve 80% of baseline authorization volume via Machinify; 2025 improvements cited
  • AI automation results (2025): real-time auto authorization rate increased by >11 points for chest CT and +16 points for cervical spine MRI
  • 2026 cost actions: SG&A, AI and other automation savings; RIF announced shortly before call; cost ramp fully in 2H 2026
  • Reserving methodology shift emphasized: conservative IBNR/reserving for new contracts creates first-half EBITDA headwind with downside protection from contract structures
  • Administrative services: noted churn in 2025 from a customer acquired by a large national plan and in-sourced; in 2026 expected to be more than offset by a $50M YoY workforce reduction and efficiencies (including the $20M Q4 2025 realized savings)

AI IconMarket Outlook

  • 2026 overall: revenue ~$2.5B midpoint (~30% growth) and adjusted EBITDA $125M midpoint; Q4 2026 run-rate adjusted EBITDA expected >$150M
  • Highmark contract: go-live May 1; expected >$550M revenue in 2026 and >$800M in 2027
  • MER outlook for 2026: ~93% midpoint; MER expected to rise at start of year, peak in Q3, then steadily improve through year-end
  • Timing/shape of 2026 EBITDA: midpoint expects $20M adjusted EBITDA in Q1 with $10M to $15M sequential improvement per quarter in Q3 and Q4 (70% EBITDA weighted to back half of 2026)

AI IconRisks & Headwinds

  • Exchange membership contraction from One Big Beautiful Bill: management assumes ~40% reduction; early indicators consistent; more driven by plans proactively stepping away from risk pools (vs subsidy changes alone)
  • Specialty T&S exchange impact: onetime ~$40M revenue headwind to 2026 and unfavorable mix shift; excluding exchange, T&S shows modest underlying growth
  • New contract reserving/implementation ramp creates temporary 2026 EBITDA headwind of $25M at midpoint (shifted from prior expectation of breakeven); also tied to higher-than-expected membership volumes for midyear launches
  • MER volatility risk: MER expected to rise early in 2026 due to higher reserve requirements for new contracts implemented Jan 1; Q&A emphasized conservative reserves despite enhanced contract retroactive fee adjustments
  • Administrative services churn: one acquired customer in-sourced services (named as a 2025 event); churn deemed meaningful and must be offset by workforce reductions/efficiencies
  • Capital market/dislocation risk: Q&A highlighted concern that EVH debt trades at a significant discount; management did not commit to open-market buybacks, stating focus remains on deleveraging and ramp execution

Sentiment: MIXED

Note: This summary was synthesized by AI from the EVH Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (EVH)

© 2026 Stock Market Info — Evolent Health, Inc. (EVH) Financial Profile